Source: Annual Congress 2005 - Advancements in diffuse parenchymal lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Dass, C. Fernandes, B. Griffiths, P. Emery, M. T. Henry (Leeds, United Kingdom). Safety and efficacy of prolonged treatment of fibrosing alveolitis in scleroderma with cyclophosphamide. Eur Respir J 2005; 26: Suppl. 49, 1798

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005 Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Treatment of exacerbations of fibrotic idiopathic interstitial pneumonias with cyclophosphamide and corticosteroids Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 A 12-week combination of clarithromycin and prednisone for the treatment of cryptogenic and radiation-induced organising pneumonia Source: International Congress 2015 – New insights into IIPs Year: 2015 Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 High-dose inhalation corticosteroids in conjunction with plasmapheresis in the treatment of patients with acute variant of exogenic allergic alveolitis (EAA) Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017 Year: 2017 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Hypersensitivity pneumonitis associated with the use of temozolomide Source: Eur Respir J 2009; 33: 931-934 Year: 2009 Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses Source: Eur Respir J 2011; 38: 1487-1489 Year: 2011 High-dose acetylcysteine in idiopathic pulmonary fibrosis Source: ISSN=ISSN 1810-6838, ISBN=, page=358 Year: 2006 Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia Source: Eur Respir J 2015; 45: 1624-1631 Year: 2015 Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease Source: International Congress 2017 – Novel and old entities Year: 2017 Combination of pentoxifylline and steroids in sarcoidosis treatment Source: Eur Respir J 2005; 26: Suppl. 49, 269s Year: 2005 Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019